<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03969550</url>
  </required_header>
  <id_info>
    <org_study_id>29305436</org_study_id>
    <nct_id>NCT03969550</nct_id>
  </id_info>
  <brief_title>Do CCR5 Antagonists Improve the Overall Survival of Patients With AIDS-related Progressive Multifocal Leucoencephalopathy?</brief_title>
  <official_title>Do CCR5 Antagonists Improve the Overall Survival of Patients With AIDS-related Progressive Multifocal Leucoencephalopathy?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Progressive multifocal leucoencephalopathy (PML) is a demyelinating disease caused by John
      Cunningham virus (JCV) reactivation. Numerous molecules have been overstated because there
      were inaccurately tested in non-rigorous clinical trial.

      The objective is to draw lessons from repeatedly false hopes of unconfirmed PML treatments
      that might contribute to prescribing ineffective drugs on claimed efficacy in case reports or
      small series and by failing to respect the need for clinical trial evaluation before
      authorizing their widespread use.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2008</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>8 years</time_frame>
  </primary_outcome>
  <enrollment type="Actual">34</enrollment>
  <condition>AIDS</condition>
  <condition>Progressive Multifocal Leucoencephalopathy (PML)</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Measure of overall survival</intervention_name>
    <description>Measure of overall survival among AR-PML (AIDS-related PML) patients, exposed or not to maraviroc (MVC), and immune reconstitution inflammatory syndrome (IRIS) onset.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with AR-PML, exposed or not to maraviroc, as part of combined antiretroviral
        treatment (cART).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with AR-PML

          -  Diagnosed between January 2008 and December 2015

          -  Followed in one of the four University Hospitals' Infectious Diseases Departments

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 29, 2019</study_first_submitted>
  <study_first_submitted_qc>May 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2019</study_first_posted>
  <last_update_submitted>May 29, 2019</last_update_submitted>
  <last_update_submitted_qc>May 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Maraviroc</keyword>
  <keyword>John Cunningham virus (JCV)</keyword>
  <keyword>Immune reconstitution inflammatory syndrome (IRIS)</keyword>
  <keyword>Combined antiretroviral treatment (cART)</keyword>
  <keyword>Overall survival (OS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukoencephalopathy, Progressive Multifocal</mesh_term>
    <mesh_term>Leukoencephalopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

